Back to Search Start Over

Identification of NIFTP-Specific mRNA Markers for Reliable Molecular Diagnosis of Thyroid Tumors.

Authors :
Lee, So-Yeon
Park, Jong-Lyul
Kim, Kwangsoon
Bae, Ja Seong
Kim, Jae-Yoon
Kim, Seon-Young
Jung, Chan Kwon
Source :
Endocrine Pathology; Sep2023, Vol. 34 Issue 3, p311-322, 12p
Publication Year :
2023

Abstract

Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a low-risk thyroid tumor with a favorable prognosis. Nonetheless, differentiating NIFTP from other thyroid tumors remains challenging, necessitating reliable diagnostic markers. This study is aimed at discovering NIFTP-specific mRNA markers through RNA sequencing analysis of thyroid tumor tissues. We performed mRNA expression profiling for 74 fresh frozen thyroid tissue samples, including NIFTP and benign and malignant follicular-cell-derived tumors. NIFTP/malignant tumors showed 255 downregulated genes and 737 upregulated genes compared to benign tumors. Venn diagram analysis revealed 19 significantly upregulated and 7 downregulated mRNAs in NIFTP. Akaike information criterion analysis allowed us to select OCLN, ZNF423, LYG1, and AQP5 mRNA markers. We subsequently developed a predictive model based on logistic regression analysis using these four mRNAs, which we validated in independent samples (n = 90) using a qRT-PCR assay. This model demonstrated high accuracy in predicting NIFTP in discovery dataset (AUC (area under the receiver operating characteristic) = 0.960) and the validation dataset (AUC = 0.757). Our results suggest that OCLN, ZNF423, LYG1, and AQP5 mRNA markers might serve as reliable molecular markers for identifying NIFTP among other thyroid tumors, ultimately aiding in accurate diagnosis and management of NIFTP patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10463976
Volume :
34
Issue :
3
Database :
Complementary Index
Journal :
Endocrine Pathology
Publication Type :
Academic Journal
Accession number :
172039782
Full Text :
https://doi.org/10.1007/s12022-023-09781-1